ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
Enanta Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $332.32M | $197.05M |
| Enterprise Value | $142.82M | $106.56M |
| PS Ratio | 5.09 | 3.93 |
| PB Ratio | 3.29 | 2.14 |
| P/TBV Ratio | 3.29 | 2.46 |
Enterprise value
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.19 | 2.69 |
Income (trailing twelve months)
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $65.26M | $57.94M |
| Operating Income | -$58.73M | -$21.44M |
| Pretax Income | -$63.13M | -$14.45M |
| Net Income | -$63.23M | -$22.46M |
| EBITDA | -$53.82M | -$16.91M |
Margins
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -90.0% | -44.5% |
| Pretax Margin | -96.7% | -13.0% |
| Profit Margin | -96.9% | -39.2% |
| EBITDA Margin | -82.5% | -31.3% |
| FCF Margin | -56.6% | -8.85% |
Returns
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -70.1% | -53.1% |
| Return on Assets (ROA) | -21.2% | -41.0% |
| Return on Capital Employed (ROCE) | -24.2% | -37.8% |
Growth
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -8.82% | 2.25% |
| Revenue Growth (5Y CAGR) | -11.8% | 6.42% |
Balance sheet
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $189.51M | $62.42M |
| Net Cash (Debt) | $189.51M | $15.68M |
| Net Cash Per Share | $6.51 | $0.65 |
| Equity (Book Value) | $101.07M | $48.79M |
| Book Value Per Share | $3.47 | $1.36 |
| Tangible Book Value | $101.07M | $23.06M |
| Working Capital | $149.45M | $75.77M |
Financial position
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.76 | 3.30 |
| Quick Ratio | 3.62 | 2.39 |
| Interest Coverage | -4.55 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$35.32M | -$12.35M |
| Capital Expenditures | -$1.62M | -$1.06M |
| Free Cash Flow | -$36.94M | -$20.28M |
| FCF Per Share | -$1.27 | -$0.41 |
Efficiency
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.22 | 0.38 |
| Revenue Per Employee | $543.82K | $398.96K |
| Profits Per Employee | -$526.92K | -$732.08K |
| Employee Count | 120 | 73 |
Dividends and yields
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -19.0% | -21.2% |
| FCF Yield | -11.1% | -7.64% |
Shares
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 29,125,400 | 59,128,900 |
| Shares Change (QoQ) | 0.20% | 0.54% |
| Float | 26,812,700 | 48,744,500 |
| Shares Held by Insiders | 7.94% | 11.8% |
| Shares Held by Institutions | 93.6% | 59.4% |
Taxes
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $99.00K | $91.50K |
Scores
| Measure | Enanta Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -0.93 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Enanta Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.